Tofacitinib does not affect platelet function or coagulation in patients with ulcerative colitis
Tofacitinib treatment was not associated with increased platelet aggregation, platelet activation, or enhanced coagulation in patients with UC.
AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
We have 2 of 10 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Tofacitinib treatment was not associated with increased platelet aggregation, platelet activation, or enhanced coagulation in patients with UC.
Cellular immunotherapies represent a promising but still investigational therapeutic paradigm in IBD and robust clinical trials with standardized endpoints and long-term safety monitoring are needed before their clinical adoption.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.